How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Drug Based on Gene Therapy Market
- By Therapy Type: Ex vivo gene therapy, In vivo gene therapy, Gene editing therapy, Gene silencing therapy
- By Vector Type: Adeno-associated virus (AAV) vectors, Lentiviral vectors, Adenoviral vectors, Retroviral vectors, Non-viral vectors
- By Target Disease: Monogenic disorders, Oncological diseases, Cardiovascular diseases, Neurological disorders, Infectious diseases
- By Delivery Method: Intravenous injection, Intramuscular injection, Intrathecal injection, Intraocular injection, Direct tissue injection
- By Product Type: Gene replacement therapies, Gene addition therapies, Gene knockdown therapies, Gene editing therapies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Ex vivo gene therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Drug Based on Gene Therapy Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Gilead Sciences (Kite Pharma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bluebird Bio
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sangamo Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →uniQure
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Spark Therapeutics (a Roche company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AveXis (a Novartis company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →REGENXBIO
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Audentes Therapeutics (a subsidiary of Astellas Pharma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →MeiraGTx
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Homology Medicines
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bristol-Myers Squibb (through acquisition of Celgene)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Pfizer
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bayer (through acquisition of AskBio)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Orchard Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Ex vivo gene therapy60.3
- In vivo gene therapy8.4
- Gene editing therapy10.4
- Gene silencing therapy20.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis15.3
- Gilead Sciences (Kite Pharma)19.3
- Bluebird Bio12.3
- Sangamo Therapeutics11.9
- uniQure7.3
- Spark Therapeutics (a Roche company)5.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.4
- Europe22.7
- Asia Pacific19.1
- Latin America13.7
- Middle East and Africa9.1
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis | 85 | 90 | 87 | 92 | 93 | 99 | 91 |
| Gilead Sciences (Kite Pharma) | 83 | 85 | 84 | 84 | 83 | 83 | 84 |
| Bluebird Bio | 82 | 78 | 84 | 84 | 83 | 85 | 83 |
| Sangamo Therapeutics | 73 | 58 | 58 | 65 | 64 | 59 | 63 |
| uniQure | 69 | 69 | 74 | 75 | 54 | 77 | 70 |
| Spark Therapeutics (a Roche company) | 62 | 63 | 69 | 55 | 51 | 57 | 60 |
| AveXis (a Novartis company) | 54 | 60 | 53 | 42 | 43 | 50 | 50 |
| REGENXBIO | 53 | 53 | 59 | 60 | 35 | 36 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis
- Gilead Sciences (Kite Pharma)
- Bluebird Bio
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Gilead Sciences (Kite Pharma) | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Bluebird Bio | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Sangamo Therapeutics | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| uniQure | ✓ | ◐ | ◐ | ◐ | − | ◐ |
| Spark Therapeutics (a Roche company) | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| AveXis (a Novartis company) | ◐ | − | ◐ | − | − | − |
| REGENXBIO | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Therapy Type in North America, then scale across Drug Based on Gene Therapy Market — a $103M beachhead inside a $1.70B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Ex vivo gene therapy
Best fit — highest urgency & budget in Therapy Type.
In vivo gene therapy
Strong fit — clear ROI and a fast path to value.
Gene editing therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Vector Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Target Disease
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Drug Based on Gene Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Drug Based on Gene Therapy Market is a resilient opportunity — $4.68B by 2033, compounding at 4.7%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Vector Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Drug Based on Gene Therapy Market — a $1.57B market by 2033. Plan: grow share from 5.9% to 12.9%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.9% | 12.9% | At risk |
| Revenue | $101M | $203M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 34.2% | 44.0% | On track |
| Customer retention | 86.3% | 93.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Vector Type capability
A defensible second engine — invest in Vector Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Vector Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $24M capacity & capability investment
- Greenlight bolt-on M&A in Vector Type
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAhead
Sales deck · value proposition
Win the Drug Based on Gene Therapy Market conversation — a $10.6B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Drug Based on Gene Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Drug Based on Gene Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Drug based on CAR T-Cell Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportDrug and Pharmaceutical Machinery Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportDrug and Medical Device Testing Services Market
Market size, share, segmentation and regional forecast.
$917M market · 2025 base year
View reportDrug and Medical Device Testing Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportProtein Purification Resin Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportDrug and Medical Device Development Testing Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportDrug and Gene Delivery System Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportDrug and Alcohol Testing Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportDrug and Alcohol Monitoring Systems Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportDrug Analyzer Market
Market size, share, segmentation and regional forecast.
$535M market · 2025 base year
View reportDrug Analysis Service Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportDrug Allergens Allergy Diagnostics Allergy Diagnostics Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy